<DOC>
	<DOC>NCT01547299</DOC>
	<brief_summary>The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.</brief_summary>
	<brief_title>Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Willing to provide informed consent 18 years of age or older Histologically confirmed adenocarcinoma of the prostate Must be a candidate for radical prostatectomy and considered surgically resectable Stage T4 prostate cancer by clinical or radiologic evaluation Treatment with an investigational agent within 4 weeks prior to randomization Received therapy for other neoplastic disorders within 5 years Hypogonadism or severe androgen deficiency</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostatectomy</keyword>
	<keyword>neoadjuvant</keyword>
</DOC>